Immunotherapeutic Strategies for Alzheimer's Disease

Immunotherapy for Alzheimer's disease seeks to engage the host immune system or deliver exogenous antibodies to reduce pathological accumulations of amyloid-β and tau proteins, to modulate neuroinflammation and to preserve neuronal function. Strategies include active vaccination, in which patients generate their own antibody response to selected epitopes of amyloid-β or tau, and passive immunisation, which relies on the periodic infusion of monoclonal antibodies directed against pathological aggregates. More recent approaches target microglial receptors or the gut–brain axis to reprogramme innate immunity and promote clearance of toxic proteins. Combination vaccines are under development to elicit simultaneous humoral responses against multiple pathological species, while advanced adjuvant systems aim to maximise antibody titres without provoking T-cell–mediated autoimmunity. Clinical trials have revealed both cognitive benefits and challenges such as amyloid-related imaging abnormalities (ARIA), underscoring the need for careful titration of immune activation. Early intervention, ideally in presymptomatic stages identified by biomarkers, appears essential to intercept accumulating pathology before irreversible synaptic loss. Global efforts now emphasise translational pipelines connecting preclinical immunogenicity data with safety and efficacy endpoints in well-characterised patient cohorts.

Research from Nature Portfolio

Recent preclinical work has demonstrated the immunogenic potential of multi-epitope vaccines formulated with delta-inulin and CpG-based adjuvants. These vaccine constructs combine amyloid-β and tau B-cell epitopes on a universal T-helper platform, yielding high-titer antibodies against both protein species in murine models. In-depth 3D modelling of epitope presentation has informed design improvements, revealing that dual-epitope formats may elicit robust anti-amyloid responses but require optimisation to achieve equivalent anti-tau titres. AdvaxCpG-adjuvanted formulations were found to promote a balanced humoral profile without signs of T-cell autoreactivity, supporting their progression to advanced preclinical assessment and future human trials.

Immunotherapeutic Strategies for Alzheimer's Disease publication trend

The graph below shows the total number of articles in immunotherapeutic strategies for alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Active immunisation: Administration of antigenic peptides or proteins to induce the patient’s own antibody production against specific pathological epitopes.

Passive immunisation: Periodic infusion of exogenous monoclonal antibodies targeting amyloid-β or tau aggregates.

Amyloid-β (Aβ): A peptide derived from the amyloid precursor protein that aggregates extracellularly into plaques in the Alzheimer’s brain.

Tau protein: A microtubule-associated protein that, when hyperphosphorylated, forms intracellular neurofibrillary tangles.

Adjuvant: A substance co-administered with antigen to enhance the magnitude and durability of the immune response.

Amyloid-related imaging abnormalities (ARIA): MRI-detectable vascular changes, including oedema or microhaemorrhages, associated with antibody-mediated amyloid clearance.

Microglia: Resident immune cells of the central nervous system that can phagocytose debris and secrete cytokines in response to pathological proteins.

References

1. Mechanisms of ARIA: is it time to focus on the unique immune environment of the neurovascular unit?. Molecular Neurodegeneration (2023).
2. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease. Brain (2019).
3. Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond. Translational Neurodegeneration (2022).
4. Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules. Scientific Reports (2016).